Herpesviruses have co-speciated with several vertebrate and invertebrate animals throughout the history of evolution. In the immunocompetent human host, primary infection is usually benign, whereafter the virus is brought into life-long latency. Viral reactivation can however cause severe disease in immunocompromised, and rarely also in immunocompetent, patients. The overall aim of this thesis was to study the immunologic effects of cytomegalovirus (CMV) and herpes simplex type 1 (HSV-1) infection in neurocognitive disorders. CMV is known to promote T-cell differentiation towards a more effector-oriented phenotype, similar to what is seen in the elderly. We have addressed the frequency of CMV-specific CD8+ T-cells in Alzheimer's disease (AD). Furthermore, we have investigated whether AD patients present with a different CMV-specific immune profile, overall CD8 phenotype or inflammatory cytokine response to anti-CD3/CD28 beads, CMV pp65 and amyloid beta. Subjects with AD presented with a lower proportion of CMV-specific CD8+ T-cells compared to non-demented (ND) controls, but no differences in overall CD8 differentiation were seen. Overall, AD subjects presented with a more pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype. When PBMCs were challenged with CD3/CD28-stimulation, CMV seropositive AD subjects presented with more IFN-γ release than both CMV seronegative AD subjects and CMV seropositive ND controls. For effective screening of humoral herpesvirus immunity, both in research and in clinical practice, efficient immunoassays are needed. We have addressed the methodology of multiplex herpesvirus immunoassays and related bioinformatics and investigated antibody levels in AD patients and ND controls. Subjects with AD presented with lower levels of human herpesvirus 6 (HHV-6) IgG. However, there was no difference in HHV-6 DNA levels in PBMCs between the groups. Herpes simplex encephalitis (HSE) is a devastating disease, where antiviral treatment has greatly decreased mortality but not eliminated the associated long-term neurocognitive morbidity. We have investigated the correlation between N-Methyl-D-Aspartate Receptor (NMDAR) autoimmunity and recovery of neurocognitive functions after HSE. Approximately one quarter of all HSE cases developed NMDAR autoantibodies within 3 months after onset of disease. Antibody development was associated with an impaired neurocognitive recovery during the two year follow-up and could become an important therapy guiding factor in the future.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Spermidine (SPD) is an endogenous polyamine with polycationic structure present in the central nervous system of mammals. SPD regulates biological processes, such as Ca2+ influx by glutamatergic N-methyl-D-aspartate receptor (NMDA receptor), which has been associated with nitric oxide synthase (NOS) and cGMP/PKG pathway activation and a decrease of Na+,K+-ATPase activity in rats cerebral córtex synaptossomes. Decreased Na+,K+-ATPase activity, as well as decreased enzyme expression, directly impairs neurotransmitter signaling with deleterious consequences on learning and memory. The enzyme Na+,K+-ATPase establishes Na+ and K+ gradients across membranes of excitable cells and by this means maintains membrane potential and controls intracellular pH and volume. However, it has not been defined whether SPD modulates Na+,K+-ATPase activity in the hippocampus. In this study we investigated whether SPD alters Na+,K+-ATPase activity in slices of hippocampus from rats, and possible underlying mechanisms. Hippocampal slices and homogenates were incubated with SPD (0.05-10 μM) for 30 minutes. SPD (0.5 and 1 μM) decreased Na+,K+-ATPase activity in slices, but not in homogenates. MK-801 (100 μM), a non-competitive antagonist of NMDA receptor, arcaine (0.5 μM), an antagonist of the polyamine binding site at the NMDA receptor, and L-NAME (100 μM), a nitric oxide synthase inhibitor, prevented the inhibitory effect of SPD (0.5 μM). ODQ (10 μM), a guanylate cyclase inhibitor, and KT5823 (2 μM), a protein kinase G inhibitor, also prevented the inhibitory effect of SPD on Na+,K+-ATPase activity. SPD (0.5 and 1.0 μM) increased NO2 plus NO3 (NOx) levels in slices, MK-801 (100 μM) and arcaine (0.5 μM) prevented the effect of SPD (0.5 μM) on the NOx content. These results suggest that SPD-induced decrease of Na+,K+-ATPase activity involves NMDA/NOS/cGMP/PKG pathway. / A espermidina (SPD) é uma poliamina endógena com estrutura policatiônica presente no sistema nervoso central (SNC) de mamíferos. A SPD regula muitos processos biológicos, como o influxo de cálcio através dos receptores glutamatérgicos N-metil-D-aspartato (NMDA), o qual tem sido associado com a ativação da enzima óxido nítrico sintase (NOS) e da via de sinalização da guanosina mono fosfato cíclica/proteína quinase dependente de GMPc (GMPc/PKG). Sabe-se que uma diminuição da atividade da Na+,K+-ATPase, bem como a sua expressão, prejudica diretamente a sinalização de neurotransmissores, comprometendo tanto aprendizado e a memória. A enzima Na+,K+-ATPase estabelece os gradientes de Na+ e K+ através da membrana de células excitáveis e desta forma mantém o potencial de membrana e contribui para o controle do volume e do pH celular. No entanto, não está bem definido se a SPD modula a atividade da Na+,K+-ATPase no hipocampo de ratos. Neste estudo foi investigado se SPD altera a atividade da Na+,K+-ATPase em fatias de hipocampo de ratos, e o possível mecanismo envolvido neste processo. As fatias e o homogeneizado de hipocampo foram incubados com SPD (0,05-10 M) por 30 minutos. SPD (0,5 e 1 M) diminuíram a atividade da Na+,K+-ATPase em fatias, mas não no homogeneizado de hipocampo. MK-801 (100 μM), um antagonista não competitivo do receptor NMDA, arcaína (0,5 M), um antagonista do sítio de ligação das poliaminas no receptor NMDA, e L-NAME (100 μM), um inibidor da NOS, preveniram o efeito inibitório da SPD (0,5 M). ODQ (10 μM), um inibidor da enzima guanilato ciclase, e KT5823 (2 μM), um inibidor da proteína quinase dependente de GMPc, também preveniram o efeito inibitório da SPD sobre a atividade da Na+,K+-ATPase. SPD (0,5 e 1,0 μM) aumentaram os níveis de NO2 plus NO3 (NOx) nas fatias de hipocampo. MK-801 (100 μM) e arcaína (0,5 μM) preveniram o efeito da SPD (0,5 μM) sobre conteúdo de NOx. Estes resultados sugerem que a diminuição da atividade da Na+,K+-ATPase induzida pela SPD envolve a via de sinalização NMDA/NOS/GMPc/PKG.

Dysfunction of the N-methyl-D-aspartate (NMDA) receptor is thought to contribute to the cognitive deficits of many neurodegenerative diseases and psychiatric disorders. Cognitive symptoms of Alzheimer's disease can be treated with NMDA receptor antagonists or drugs targeting the cholinergic system; however, there are no effective treatments for cognitive deficits of schizophrenia or Huntington's disease. With the discovery of a potent and selective allosteric modulator of the NMDA receptor, there is the possibility of new treatments based on NMDA receptor functional-enhancement through neuroactive steroids, closely related in structure to the endogenous neurosteroid, cerebrosterol. The aim of this thesis was to examine steroidal modulation of the NMDA receptor both in vitro and in vivo. In chapter 2, NMDA receptor enhancement of both the synthetic and endogenous neuroactive steroids was assessed in neurons maintained in cell culture using calcium imaging techniques. Sulphation of the steroids greatly increased the efficacy of NMDA receptor enhancement compared to the unsulphated steroids. Chapters 3 and 4 investigate the potential for neuroactive steroids to treat cognitive impairments of Huntington's disease. Using a mouse model, tests were selected that were analogous to those in which patients are impaired; however, no impairments were found in the mouse model. Chapter 5, therefore, used a different model of cognitive impairment – namely, rats with a set-shifting impairment, as is seen in many psychiatric and neurological disorders, including Huntington's disease – to assess the effect of the synthetic steroid administration. Unfortunately, the rats did not show the expected impairment. The lack of reliable animal models compromised testing the efficacy of these promising NMDA receptor positive allosteric modulators. Nevertheless, the promising in vitro results suggest that there could still be therapeutic potential. In addition, the compound is a useful research tool for exploring NMDA receptor function in health and disease.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Neuroinflammation is a neuropathological finding in a number of neurodegenerative diseases. Intraperitoneal injection of lipopolysaccharide (LPS) induces neuroinflammation and memory deficit. Spermine and spermidine are endogenous polyamines that physiologically modulate the N-methyl-D-aspartate (NMDA) receptor in mammals by binding to the polyamine-binding site at the NMDA receptor. Since polyamines improve memory in cognitive tasks, we tested whether the post-training administration of spermine reverses the deficits of memory induced by LPS in the object recognition task in mice. While spermine (1 mg/kg, i.p.) increased, ifenprodil (10 mg/kg, i.p.), a noncompetitive GluN2B-containing NMDA receptor antagonist, decreased the discrimination score on novel object recognition task. Spermine, at dose that did not alter memory (0.3 mg/kg, i.p.), reversed the cognitive impairment induced by LPS (250 μg/kg, i.p.). Ifenprodil (0.3 mg/kg, i.p.) reversed the protective effect of spermine against LPS-induced memory deficits in the novel object recognition task. However, spermine failed to reverse the LPS-induced increased of cortical and hippocampal cytokines levels. The results indicate that spermine protects from LPS-induced memory deficits in mice by mechanisms other than decreasing LPS-induced cytokine production. / A inflamação periférica desencadeia a produção central de citocinas inflamatórias, gerando um quadro de neuroinflamação. Essa condição altera as transmissões no receptor N-Metil-D-Aspartato (NMDA) o que prejudica a memória e a plasticidade sináptica. A injeção de Lipopolissacarídeo (LPS) induz a neuroinflamação e prejudica a memória. A espermina e a espermidina são poliaminas endógenas que modulam fisiologicamente o receptor NMDA em mamíferos. Uma vez que as poliaminas melhoram a memória em tarefas cognitivas, investigamos se a administração pós-treino de espermina reverte o prejuízo de memória induzido por LPS sistêmico na tarefa de reconhecimento de objetos em camundongos. Enquanto a espermina (1 mg/kg, ip) aumentou, o ifenprodil (10 mg/kg, ip), antagonista não competitivo do receptor NMDA contendo GluN2B, diminuiu a discriminação na tarefa de reconhecimento de objetos. A espermina, em doses que não alteram a memória (0,3 mg/kg, ip), reverteu o dano cognitivo induzido por LPS (250 μg/kg, ip). O ifenprodil (0,3 mg/kg, ip) impediu o efeito protetor da espermina contra o prejuízo de memória induzido por LPS na tarefa de reconhecimento de objetos. No entanto, a espermina não reverteu o aumento dos níveis de citocinas pró-inflamatórias induzido por LPS no hipocampo e córtex cerebral. Os resultados do presente estudo indicam que a espermina protege a piora da memória induzida por LPS em camundongos. O mecanismo desta proteção envolve o sítio de ligação das poliaminas no receptor NMDA, e não envolve mecanismos anti-inflamatórios.

Conselho Nacional de Desenvolvimento Científico e Tecnológico / The morphine addiction is a chronic disease that involves biological, cognitive and behavioral changes developed after repeated and compulsive drug use. Even after long periods of abstinence relapses occur to users, especially when faced with situations that resemble the use thereof. The protocol of conditioned place preference (CPP) has been one of the most widely used experimental models to measure the positive reinforcing effects (conditioned place preference) and negative (conditioned place aversion) of several drugs, including morphine. Studies show that antagonists of the N-methyl-D-aspartate (NMDA) block morphine-induced CPP, suggesting that this receptor is involved in the effects of morphine. Since polyamines act at the NMDA receptor, spermidine (SPD) positive allosteric modulating shape and arcaine acting as an antagonist of the polyamine site on this receiver, the purpose of this study the effect of polyamines on the preference induced conditioned place was to evaluate morphine. Adult male Swiss mice were pre-conditioned once a day for 15 minutes for two consecutive device in the CPP, the next day days were subjected twice daily for conditioning sessions with different drugs and protocols for four consecutive days. Twenty-four hours after the last conditioning session the animals were subjected to the test. The CPP score was calculated for the time spent in the compartment paired with the drug on test day, minus the time spent in the same compartment on the second day of the preconditioning. The results of this study showed that morphine (2.5-10 mg/kg, ip) induced CPP, but not aversion induced conditioned place aversion, the SPD (3-30 mg/kg, ip) and arcaine (0.3-3 mg/kg, ip) did not preferably nor induced conditioned place aversion. However, arcaine (3 mg/kg) administered 15 min before morphine (5 mg/kg) attenuated the pre-training acquisition of morphine-induced PCL. The arcaine (3 mg/kg) administered immediately after conditioning with morphine (5 mg/kg) blocked morphine induced PCL. Also, arcaine (3 mg/kg) administered 30 min pretest blocked morphine induced expression CPP. Furthermore, the effect of arcaine on attenuate the effect of morphine was prevented by the administration of SPD before conditioning, but was not reversed by postconditioning pre-test administration and SPD. These data indicate that arcaine blocks the rewarding effect of morphine and arcaine suggests that it could be a therapeutic target in the development of drugs to treat addiction to morphine. / A adicção a morfina consiste em uma doença crônica que envolve alterações biológicas, cognitivas e comportamentais desenvolvida após o uso repetido e compulsivo da droga. Mesmo após longos períodos de abstinência ocorrem recaídas aos usuários, principalmente quando se deparam com situações que lembram o uso da mesma. O protocolo de preferência condicionada por lugar (PCL) tem sido um dos modelos experimentais mais utilizados para mensurar os efeitos reforçadores positivos (preferência condicionada por lugar) e os negativos (aversão condicionada por lugar) de diversas drogas, incluindo a morfina. Estudos mostram que antagonistas do receptor N-Metil-D-Aspartato (NMDA) bloqueiam a PCL induzida por morfina, sugerindo que este receptor está envolvido nos efeitos da morfina. Uma vez que as poliaminas atuam no receptor NMDA, a espermidina (SPD) modulando de forma alostérica positiva e a arcaína agindo como antagonista do sítio das poliaminas neste receptor, o objetivo deste estudo foi avaliar o efeito das poliaminas sobre a preferência condicionada por lugar induzida por morfina. Camundongos Swiss machos foram pré-condicionados uma vez por dia, durante 15 minutos por dois dias consecutivos no aparelho de PCL, no dia seguinte, foram submetidos, duas vezes por dia às sessões de condicionamento, com diferentes drogas e protocolos durante quatro dias consecutivos. Vinte e quatro horas após a última sessão de condicionamento os animais foram submetidos ao teste. O escore de PCL foi calculado pelo tempo gasto no compartimento pareado com a droga no dia do teste, menos o tempo gasto no mesmo compartimento no segundo dia do pré-condicionamento. Os resultados deste estudo mostraram que a morfina (2,5-10 mg/kg, i.p.) induziu PCL, mas não aversão condicionada por lugar, a SPD (3-30 mg/kg, i.p.) e arcaína (0,3-3 mg/kg, i.p.) não induziram preferência e nem aversão condicionada por lugar. No entanto, a arcaína (3 mg/kg) administrada 15 minutos antes da morfina (5 mg/kg) no pré-treino atenuou a aquisição da PCL induzida por morfina. A arcaína (3 mg/kg) administrada imediatamente após o condicionamento com morfina (5 mg/kg) bloqueou PCL induzida por morfina. Ainda, arcaína (3 mg/kg) administrada 30 min pré-teste bloqueou a expressão PCL induzida por morfina. Além disso, o efeito da arcaína em atenuar o efeito da morfina foi prevenido pela administração de SPD antes do condicionamento, mas não foi revertido pela administração pós-condicionamento e pré-teste de SPD. Estes dados indicam que arcaína bloqueia o efeito de recompensa da morfina e sugere que a arcaína poderia ser um alvo terapêutico no desenvolvimento de drogas para tratar a adicção por morfina.

Spermine (SPM) is an aliphatic amine which contains four nucleophilic centers and is found in all eukaryotic cells, including nervous cells. It belongs to the group of polyamines, which are molecules associated with both neuroprotection and neurotoxicity. The aim of this study was to investigate the effects of spermine on some parameters of toxicity induced by striatal administration of quinolinic acid (QA), an experimental model of Huntington s disease in adult and male Wistar rats. The intrastriatal administration of QA (180 nmol/site) induced contralateral rotations and increase the number of contralateral body swings. The previous striatal administration of SPM caused mixed effects: at the dose of 0.1 nmol/site increased the number of contralateral rotations; but at 10 nmol/site it reduced both the number of rotations and the contralateral body swings induced by QA. The mechanism by which SPM decreases these motor alterations is probably through its interaction with the NMDA receptor, since the co-administration with arcaine (antagonist of polyamine binding sites on this receptor) reversed its protective effect. The increase of protein carbonyl content induced by QA (180 nmol/site) in striatum of rats was prevented by the administration of 10 nmol/site of SPM. Besides, the bilateral striatal injection of QA (180 nmol/site) impaired the performance in the recognition memory task. The post-training striatal administration of SPM (0.1 and 1 nmol/site) reversed the QA-induced cognitive deficit. It was also evaluated whether spermine prevented QA-induced neuromorphological alterations. QA caused striatal neuronal degeneration and reactive astrogliosis. SPM, at the dose that improved the cognitive performance (0.1 nmol/site), had no effect on striatal neuronal degeneration but reversed the intense astrocytic reaction induced by QA. These results suggest that SPM has neuroprotective properties, presenting a dose dependent pattern of polyamine, in this experimental model of Huntington disease. / A espermina (SPM) é uma amina alifática, contendo quatro centros nucleofílicos e é encontrada em todas as células eucarióticas, incluindo células nervosas. Ela pertence ao grupo das poliaminas, moléculas responsáveis tanto por efeitos neuroprotetores quanto neurotóxicos. O objetivo do presente trabalho foi investigar os efeitos da SPM sobre alguns parâmetros de toxicidade induzidos pela administração estriatal de ácido quinolínico (AQ), um modelo experimental da doença de Huntington em ratos Wistar machos adultos. A administração intraestriatal unilateral de AQ (180 nmol/sítio) induziu o aparecimento de rotações contralaterais e aumento do percentual de balanços corporais contralaterais. A prévia administração estriatal de SPM mostrou efeitos diversos: na dose de 0,1 nmol/sítio aumentou o número de rotações; porém na dose de 10 nmol/sítio ela diminuiu tanto o número de rotações quanto o percentual de balanços corporais contralaterais induzidos pelo AQ. O mecanismo pelo qual a SPM diminui estas alterações motoras é, provavelmente, devido à sua interação com o receptor NMDA, uma vez que sua co-administração com a arcaína (antagonista do sítio das poliaminas neste receptor) reverteu o efeito protetor da mesma. A administração de 10 nmol/sítio de SPM preveniu o aumento do conteúdo de proteína carbonil induzida pela injeção de AQ (180 nmol/sítio) no estriado de ratos. Além disso, foi observado prejuízo cognitivo na tarefa de reconhecimento de objetos após a injeção estriatal bilateral de AQ (180 nmol/sítio). A administração estriatal póstreino de SPM (0,1 e 1 nmol/sítio) reverteu este déficit cognitivo induzido pelo AQ. Para avaliação das alterações neuromorfológicas neste modelo foram observadas degeneração neuronal e reação astrocitária. O AQ aumentou significativamente a degeneração de neurônios estriatais e a astrogliose reativa. A SPM, na menor dose que melhorou o desempenho cognitivo (0,1 nmol/sítio), não teve efeito sobre a degeneração neuronal estriatal; no entanto, ela foi capaz de reverter a intensa reação astrocitária induzida pela injeção de AQ. Estes resultados sugerem que a SPM tem propriedades neuroprotetoras, que apresentam um padrão dependente da dose da poliamina, neste modelo experimental da doença de Huntington.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Lesões sistêmicas peri e pré-natais alteram o desenvolvimento do SNC, levando a problemas cognitivos e motores em crianças que podem perdurar por toda a vida. Um tipo particular de lesão é a hipóxia-isquemia (HI), caracterizada pela interrupção momentânea ou permanente do fluxo sanguíneo. Um dos mecanismos propostos para as lesões decorrentes da HI é a excitotoxicidade glutamatérgica. O uso de inibidores da neurotransmissão glutamatérgica tem sido estudados em diversos modelos de HI. Neste trabalho, avaliamos os efeitos morfofuncionais da administração de um antagonista não-competitivo do receptor de glutamato NMDA sobre o desenvolvimento do cerebelo. Ratas no 18 dia de gestação foram anestesiadas, os cornos uterinos expostos e as 4 artérias uterinas obstruídas por 45 minutos (Grupo H). Animais controle tiveram os úteros expostos, sem a obstrução (Grupo S). Após a cirurgia a gestação prosseguiu. Somente animais nascidos a termo foram utilizados. Um dia após o nascimento, metade de cada ninhada foi designada para receber MK801, 0,3mg/kg/dia, (grupos SM e HM) e a outra metade recebeu solução salina (grupos SS e HS), por 5 dias. Após anestesia e perfusão-fixação com paraformaldeído 4% aos 9, 23, 30 e 60 dias pós-natais, cortes parassagitais do cerebelo foram obtidos em criótomo e submetidos à imunohistoquímica para calbindina, GFAP, GLAST, PDGFRα e MBP. A partir de 45 dias de vida, os animais foram testados em vários de testes comportamentais: labirinto em cruz elevado (LCE), campo vazado (CV), ROTAROD, teste de caminhada sobre barras (ladder test) e teste do comprimento da passada (stride length). Aos 9 dias, a espessura da árvore dendrítica era menor nos animais SM, HS/HM, demonstrando efeitos deletérios tanto do MK801 quanto da HI. Menor número de células PDGFRα+ foi observado nos animais HS/HM, sem efeitos da administração de MK801. Aos 23 dias, maior número de células PDGFRα+ foi observado nos animais HM comparado aos outros 3 grupos, indicando efeito neuroprotetor do MK801. Nessa idade, menor número de fibras mielinizadas (MBP+) foi observada nos animais HS, e a administração de MK801 parece reverter estes efeitos. Aos 9 dias a distribuição de GLAST estava alterada nos animais HS, com os efeitos da HI parcialmente revertidos pelo MK801. Não foram observados efeitos da HI ou do MK801 sobre comportamentos relacionados a ansiedade pelo LCE, assim como na latência de queda no ROTAROD. HI piora a performance motora no ladder test. No teste do CV, não observamos efeitos da HI sobre a busca por novidade assim como sobre a atividade locomotora espontânea. No entanto, MK801 diminui comportamentos de autolimpeza e a atividade locomotora espontânea. Menor variação das passadas foi observada em decorrência da administração de MK801 no stride length, com nenhum efeito da HI. Nossos resultados demonstram que a inibição do receptor NMDA tem um efeito neuroprotetor sobre os progenitores de oligodendrócitos e mielinização, provavelmente pela manutenção da capacidade proliferativa por um período maior. A atividade do receptor NMDA exerce importante papel na diferenciação das células de Purkinje, assim como na distribuição do transportador GLAST, corroborando a importância deste receptor na gênese das lesões causadas pela HI. / Peri and prenatal systemic lesions alter CNS development leading to motor and cognitive problems in children that might persist throughout life. A particular kind of injury, the hypoxic ischemic (HI), is characterized by a permanent or temporary blockage of blood flow. One of the proposed mechanisms downstream from a HI event is called glutamatergic excitotoxicity. The administration of glutamate inhibitors has been studied in HI models for several years. In this work, we evaluated the effects of administration of a non-competitive antagonist of glutamate receptor, NMDA, on cerebellar development and behavioral tests of HI animals. Pregnant rats in the 18th gestational day were anesthetized, the uterine horns were exposed and the four uterine arteries were clamped for 45 minutes (group H). Sham controls had the uterine horns exposed, but no arteries were clamped (group S). Gestation proceeded after surgery. Only full term animals were used. One day after birth half the animals was assigned to receive either SALINE (groups SS and HS) or MK801 (groups SM and HM). Animals were anesthetized and perfused with 4% paraformaldehyde at 9, 23, 30 and 60 days of age. Parasagittal cerebellar sections were submitted to Calbindin, GFAP, GLAST, PDGFRα and MBP immunohistochemistry. Beginning at P45 animals were subjected to a battery of behavioral tests: elevated plus maze (EPM), hole board (HB), ROTAROD, ladder test and stride length. At P9 the dendritic tree of Purkinje cells were thinner in SM, HS/HM animals, indicating that both HI and MK801 are deleterious regarding this Purkinje cell differentiation. A lower number of PDGFRα+ cells was observed in HS/HM animals, with no effects of MK801 administration. At P23 a greater number of PDGFRα+ cells was found in HM animals when compared to the other 3 groups, demonstrating a neuroprotector effect of MK801. A lower number of myelinated fibers (MBP+) was observed in HS animals at P9, and MK801 administration reverse this effect. At P9, GLAST distribution was altered in HS animals, and MK801 partially reverse this altered distribution. No effects of HI and MK801 were observed in the EPM and ROTAROD tests. HI decreased motor performance of hind limbs in the ladder test, though no effect of MK801 was noted. In the HB test, we do not observe HI effects regarding the novelty seeking behavior and locomotor activity, otherwise the administration of MK801 decreased the number of grooming and locomotor activity. In the stride length test, we do not observed effects of HI although MK801 augmented the length variation of the fore limbs. Our results show that inhibition of NMDA receptors exerts a neuroprotector effect on oligodendrocyte progenitor cells and myelination, probably by temporarily inhibiting differentiation of those, providing more time to proliferate. NMDA activity exerts a crucial role in Purkinje cell differentiation as well as in GLAST distribution. Taken together our results lead us to conclude that NMDA receptor activity has an important role in the genesis of lesions caused by HI events.

La maladie d’Alzheimer (MA) est une maladie neurodégénérative du système nerveux central qui se caractérise notamment par l’accumulation de peptide beta-amyloïde (Aβ) dans le tissus nerveux. Dans la première partie de cette thèse nous avons montré que l’interaction des oligomères Aβ1-42 de haut poids moléculaire avec la membrane plasmique des cellules PC12 différenciées ou des cellules nerveuses (neurones et astrocytes primaires) provoque des variations de la [Ca2+]i dépendant de l’activation des récepteurs NMDA. Dans la seconde partie nous avons montré qu’une pré-exposition des cellules PC12 et des cellules nerveuses à de faibles concentrations de peptide Aβ module l’interaction ultérieure des oligomères avec la membrane plasmique. Enfin dans le cadre d’une collaboration avec l’entreprise Innovative Health Diagnostics (IHD) nous avons participé à la caractérisation d’une sonde amyloïde fluorescente développée pour réaliser des tests de détection de la MA à partir d’échantillons sanguins. / Alzheimer’s disease (AD) is a neurodegenerative disease of the central nervous system which is characterized in particular by the accumulation of beta amyloïde peptide (Aβ) in nerve tissues. In the first part of this thesis we showed that the interaction of high molecular weight Aβ1-42 oligomers with the plasma membrane of differenciated PC12 or nerve cells (neurons and astrocytes) triggers variations of their depending on the activation of the NMDA receptors. In the second part we showed that a pre-exposure of PC12 and nerve cells with low concentrations Aβ1-42 of modulates the later interaction of oligomers with the plasma membrane. Finally in collaboration with the company Innovative Health Diagnostics (IHD) we participated in the characterization of a fluorescent amyloid probe developed to realize detection test of AD from blood samples.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / The memory may be studied according with memory's phases, which is acquisition, consolidation and recall. Memories once consolidated, are no more susceptible to interventions, but when reactivated, some of these memories again become labile and vulnerable, and to persist need to have a new stabilization process called reconsolidation. Previous studies described that endogenous polyamines, spermine and spermidine, which bind and modulate the activity of NMDA receptors are involved in memory acquisition and consolidation. However there are no studies showing the effect of these drugs on memory reconsolidation. Accordingly, the aim of this study was investigate the effect of polyamines on fear memory reconsolidation in rats. Male Wistar rats were trained in a fear conditioning apparatus using a 0.4 mA footshock as unconditioned stimulus. Twenty four hours after training, animals were re-exposed to the apparatus in the absence of shock (reactivation session). Immediately after the reactivation session, SPD (1 30 mg/kg, i.p.), the antagonist of the polyamine binding site at the NMDA receptor, arcaine (0.1 10 mg/kg, i.p.) or spermidine plus arcaine were injected, and the animals were tested in the same apparatus 24 h later. Freezing scores at testing were considered a measure of memory. While SPD (3 and 10 mg/kg) improved, arcaine (1 and 10 mg/kg) impaired memory reconsolidation. These drugs had no effect on memory if they were administered in the absence of reactivation, or 6 h after reactivation session. Arcaine (0.1 mg/kg, i.p.) prevented SPD (3 mg/kg)-induced improvement of memory reconsolidation. Accordingly, SPD (1 mg/kg) prevented arcaine (10 mg/kg)-induced impairment of memory reconsolidation. The amnesic effect of arcaine was not reversed by arcaine administration prior to test, ruling out state dependence in this effect. These results suggest that systemic administration of polyamine binding site ligands modulate memory reconsolidation, however further studies are required to elucidate the mechanism by which polyamines modulate memory reconsolidation. / A memória pode ser estudada de acordo com as suas fases, que são a aquisição, a consolidação e a evocação. As memórias, uma vez consolidadas, não podem mais ser modificadas, porém quando reativadas, ou seja, quando recuperadas, muitas destas voltam a se tornar instáveis e vulneráveis e para que persistam precisam passar por um novo processo de estabilização, chamado reconsolidação. Têm sido descrito que as poliaminas endógenas, espermidina e espermina, que se ligam e modulam a atividade do receptor NMDA, estão envolvidas na aquisição e na consolidação da memória. Contudo, não há trabalhos mostrando o efeito destas substâncias na reconsolidação da memória. Desta forma, o objetivo deste estudo foi verificar o efeito das poliaminas na reconsolidação da memória de medo em ratos. Para isso, ratos machos adultos foram treinados na tarefa de medo condicionado contextual, onde receberam três choque de 0,4 mA, com intervalo de 40 seg entre cada choque e, 24 horas após, os animais foram recolocados no aparelho do treino por um período de 3 min, na ausência de choque, para reativar a memória. Após a reativação foi administrado, pela via intraperitoneal, salina, espermidina (1-30 mg/kg), arcaína (0,1-10 mg/kg) ou espermidina mais arcaína e vinte e quatro horas após, os animais foram testados, onde foi avaliado a imobilidade destes durante 6 min. Foram realizados experimentos controles para avaliar a especificidade das drogas no processo de reconsolidação. Além disso, foi avaliado se o possível efeito da arcaína na reconsolidação poderia ser explicado por dependência de estado. Assim, enquanto a espermidina (3 e 10 mg/kg) melhorou, a arcaína (1 e 10 mg/kg) piorou a reconsolidação da memória. Estas drogas não tiveram efeito sobre a memória quando foram administradas na ausência da reativação ou 6 horas após. A arcaína (0,1 mg/kg) preveniu a melhora da reconsolidação da memória induzida pela espermidina (3 mg/kg) e por sua vez, a espermidina (1 mg/kg) preveniu o prejuízo da reconsolidação da memória induzido pela arcaína (10 mg/kg). O efeito amnésico da arcaína não foi revertido pela administração da mesma dose de arcaína antes do teste, descartando a hipótese de dependência de estado para o efeito da arcaína na reconsolidação. Estes resultados sugerem que a administração sistêmica dos ligantes do sítio de ligação das poliaminas do receptor NMDA modulam a reconsolidação da memória, todavia são necessários mais estudos a fim de elucidar o mecanismo pelo qual as poliaminas modulam a reconsolidação da memória.

La schizophrénie est un trouble mental débilitant qui se caractérise par des perturbations de la pensée, des émotions et de la cognition. Ces processus d’intégration fonctionnelle sont généralement associés à des oscillations bioélectriques cérébrales synchrones dans la bande de fréquence gamma (30-80 Hz), lesquelles sont aussi altérées chez des patients souffrant de schizophrénie. Ce travail de thèse vise à développer des méthodes et des outils pour étudier les mécanismes neuronaux sous-tendant les altérations de ces oscillations physiopathologiques. Pour ce faire, nous avons développé des modèles de rongeurs de laboratoire pour la schizophrénie. Nous avons démontré que des modifications génétiques ou pharmacologiques conduisent à des perturbations des oscillations gamma et que des médicaments antipsychotiques peuvent les moduler. / Schizophrenia is a debilitating mental disorder that is characterised by a breakdown in normal thought processes, blunted emotional responses and a variety of cognitive difficulties. Gamma frequency (30 – 80 Hz) oscillations are associated with many processes that are disrupted in people with schizophrenia memory, perception and attention. This thesis aimed to develop methods and tools to investigate the basic mechanisms that underlie the alterations in gamma frequency brain activity that are observed in patients suffering from schizophrenia. To do this we developed a variety of experimental animal models for schizophrenia. We successfully demonstrated that both genetic and pharmacological changes lead to alterations in gamma oscillations and that antipsychotic medications can modulate them.